Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mesalazine controlled release - Ferring

Drug Profile

Mesalazine controlled release - Ferring

Alternative Names: Mesalamine granules - Ferring; Pentasa; Pentasa® controlled release 500mg tablets; Pentasa® prolonged release granules 1g/2g/4g; Pentasa® Sachet; PS-QD

Latest Information Update: 16 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ferring Pharmaceuticals
  • Developer Ferring Pharmaceuticals; Kyorin Pharmaceutical; Takeda
  • Class Aminosalicylic acids; Anti-inflammatories; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis

Most Recent Events

  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 19 Sep 2018 Ferring Pharmaceuticals completes a phase III trial for Ulcerative Colitis in USA, Bulgaria, Canada, Latvia, Hungary, Mexico, Poland, Russia, Switzerland, Serbia, Ukraine and Belgium (PO, once-daily granules 2g ) (NCT02522780) (EudraCT2015-002558-11)
  • 03 Apr 2018 Ferring Pharmaceuticals completes a phase III trial for Ulcerative colitis in USA, Belgium, Bulgaria, Latvia, Mexico, Hungary, Canada, Poland, Russia, Switzerland, Ukraine and Serbia (NCT02522767)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top